Google
GHRS — GH RESEARCH PLC (Healthcare >> Biotechnology)
GHRS FAQ
What is GHRS's ROE?
GH RESEARCH PLC reports a Return on Equity (ROE) of -21.42%.
What is GHRS's dividend yield?
GH RESEARCH PLC offers a dividend yield of 0.00%.
What is GHRS's Deepscope Quality Score?
Deepscope rates GHRS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GHRS?
Deepscope's AI Timing Score for GHRS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GHRS belong to?
GH RESEARCH PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 21.43
Price
-1.82
(-7.83%)
Day Change
|
|
|---|
GHRS, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 21.43 |
| PBV / Sector |
6.06 / 4.63
|
| Earning Per Share | -0.76 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
5.41 M
GREAT
|
| Average 1W Daily Value |
6.65 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:25 |
| Symbol | GHRS |
| Name | GH RESEARCH PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 68.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,595.16 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Joshua Dawson House, Dublin, Ireland, D02 RY95
Phone: 353 1 437 8334
Website: https://www.ghres.com
Employees: 73
Sector: Healthcare >> Biotechnology
Description: GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
